Publication at First Faculty of Medicine |
2019
Abstract
Ankylosing spondylitis (AS) is an inflammatory rheumatic disease that affects axial skeleton characterized by inflammatory back pain and structural changes of the axial skeleton that can be seen using imagining techniques. These changes may lead to spine damage with re-sulting functional changes.
Timely diagnosis together with adequate treatment and regime adjustments leads to remission, or at least to low disease activity. Secukinumab is fully human monoclonal antibody inhibiting interleukine 17 that exhibited good clinical efficacy in the program of MEASURE clinical studies and is currently used not only in the therapy of ankylosing spondylitis and psoriatic arthritis.